Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/133707
DC Field | Value | |
---|---|---|
dc.title | Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT) | |
dc.contributor.author | McCarthy, T. | |
dc.contributor.author | Dramusic, V. | |
dc.contributor.author | Carter, R. | |
dc.contributor.author | Costales, A. | |
dc.contributor.author | Ratnam, S.S. | |
dc.date.accessioned | 2016-12-20T08:39:09Z | |
dc.date.available | 2016-12-20T08:39:09Z | |
dc.date.issued | 1995 | |
dc.identifier.citation | McCarthy, T., Dramusic, V., Carter, R., Costales, A., Ratnam, S.S. (1995). Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT). Maturitas 22 (1) : 13-23. ScholarBank@NUS Repository. | |
dc.identifier.issn | 03785122 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/133707 | |
dc.description.abstract | Objectives: To compare the occurrence of climacteric symptoms at two points in the cycle, identified as minE (phase of minimum estrogen effect) and MaxP (phase of maximum progesterone effect). Methods: Prospective randomized cross-over study in postmenopausal women currently on HRT comparing two opposed, sequential formulations: a regimen of 21 tablets containing estradiol valerate (EV) opposed with cyproterone acetate (CPA) in the last 10 tablets, versus a regimen of 28 tablets of conjugated equine estrogens (GEE), the last 12 tablets of which were taken together with norgestrel (NG). Outcome measures: Incidence of 24 climacteric complaints assessed at the specified days of the cycle corresponding to mine (day 6 or 7) and MaxP (day 27 or 28) Results: Contrary to the hypothesis that estrogen- dependent symptoms will recur at mine of the 21-day regimen, no significant differences were noted with the regimen containing 28 days of CEE, which served as the control. There were more complaints with the CEE + NG formulation at both mine and MaxP. Of the 38 patients, 63% preferred the EV + CPA regimen, 18.4% the CEE + NG regimen and 18.4% rated both preparations as equal. Conclusions: The 7-day pause in the 21-day formulation containing EV + CPA did not affect efficacy; it was as effective in relieving climacteric symptoms as the regimen containing 28 days of estrogen. Based on the frequency of complaints both at mine and MaxP, the EV + CPA formulation induced a more acceptable symptom and mood profile. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/0378-5122(95)00905-Z | |
dc.subject | Conjugated equine estrogens | |
dc.subject | Cyproterone acetate | |
dc.subject | Estradiol valerate | |
dc.subject | MaxP | |
dc.subject | minE | |
dc.subject | Norgestrel | |
dc.subject | Opposed sequential HRT | |
dc.subject | Symptom and mood profile | |
dc.type | Article | |
dc.contributor.department | OBSTETRICS & GYNAECOLOGY | |
dc.description.sourcetitle | Maturitas | |
dc.description.volume | 22 | |
dc.description.issue | 1 | |
dc.description.page | 13-23 | |
dc.description.coden | MATUD | |
dc.identifier.isiut | A1995RB54400003 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.